Merck’s Mevacor not approved
FDA found Merck's third Rx-to-OTC switch application for OTC cholesterol-lowering Mevacor Daily (lovastatin/20mg) "not approvable." In a Jan. 25 release, the firm said FDA's letter responding to its application indicated the drug's approval would require "a revised label and additional data from Merck in order to gain marketing approval." "We are evaluating the conditions put forth by the agency in the letter to determine a path forward, and no decision is made at this time for the future of our Mevacor efforts," a spokesman forthe Whitehouse, N.J.-based firm told "The Tan Sheet." At a Dec. 13 meeting, FDA advisory committees recommended against approving the switch. The firm was also unsuccessful in gaining OTC approval for the drug in 2000 and 2005.....
More from Archive
The US FTC’s contention that ‘notice and choice’ has failed as the cornerstone of consumer privacy regulation and must be abandoned in favor of data minimization and other more stringent measures does not adequately account for the complexity of business practices and consumer behavior, FTC commissioner Melissa Holyoak asserted at the NAD’s 2024 Annual Conference.
FTC Commissioner Melissa Holyoak says the agency has acted outside the bounds afforded by Congress, citing several areas within consumer protection, including a recent update to the final rule for the Health Breach Notification Rule and the commission’s use of notices of penalty offense to serve as the basis for Section 5 settlements.
At one year, TikTok Shop conjures the early days of Amazon, representing the ‘Wild West’ of beauty ecommerce, said co-founders of private label and contract manufacturing company KO-Pack at the IBA Cosmetics Convergence Fall 2024 Virtual Symposium, “The Promise and Pitfalls of TikTok Shop.”
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
More from HBW Insight
Four months into session, no bills have been introduced in Congress to authorize FDA to establish a regulatory pathway for the lawful use of hemp ingredients in products other than drugs or propose some other solution to the federal conundrum present since lawmakers in 2018 de-scheduled hemp.
The US Food and Drug Administration has released a roadmap to adopt new approach methodologies in lieu of animal testing for monoclonal antibody therapies and other drugs, which may include OTC drugs though the proposal does not specifically include cosmetics.
An application for melatonin as an OTC medicine is on the agenda for the next German switch committee meeting, despite the hormone being widely available in food supplements. Acyclovir as a buccal tablet and second-generation antihistamine rupatadine are also up for discussion.